Clinical Trials Logo
  1. Home
  2. Glioma
  3. NCT04216537
  4. Details
NCT04216537 Clinical Trial

Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas

Glioma Clinical Trial

Official title:
Survival Significance and Clinical Characteristics of Molecular Pathology and Genetic Variation in Brain Gliomas

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04216537
Other study ID # GiomaMG-1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date June 1, 2025

Study information
Verified date February 2021
Source The First Affiliated Hospital of Zhengzhou University
Contact Zhenyu Zhang, Dr.
Phone +86 17839973727
Email fcczhangzy1@zzu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology and genetic data. This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Description:

Precise classification based on molecular and genetic biomarkers/subgroups for gliomas is challenging. This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and genetic data (Whole exome sequencing, RNA sequencing, proteomics, etc). This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Recruitment information / eligibility
Status Recruiting
Enrollment 3000
Est. completion date June 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 1 Year to 95 Years
Eligibility Inclusion Criteria: - Patients must have radiologically and histologically confirmed diagnosis of primary glioma - Life expectancy of greater than 3 months - Must receive tumor resection - Must have sufficient fresh frozen tissues for NGS - Signed informed consent Exclusion Criteria: - No gliomas - No sufficient amount of tumor tissues for detection of molecular pathology - Patients who are pregnant or breast feeding - Patients who are suffered from severe systematic malfunctions - Do not have sufficient fresh frozen tissues for NGS

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Glioma groups based on molecular pathology or genetic variation
Patients with newly diagnosed glioma that receive tumor resection

Locations
Country Name City State
China Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (1)
Lead Sponsor Collaborator
The First Affiliated Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) The length of time from enrollment until the time of death (OS, overall survival) From enrollment to death of patients. Estimated about 5 years.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04539574 - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors N/A
Enrolling by invitation NCT04461002 - Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Completed NCT03242824 - The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma Phase 2
Recruiting NCT04186832 - Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy N/A
Completed NCT00424554 - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) Phase 2
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT02805179 - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma Phase 2
Terminated NCT04556929 - Enhanced Detection in Glioma Excision N/A
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Recruiting NCT06043232 - MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Not yet recruiting NCT06043765 - Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training N/A
Not yet recruiting NCT05025969 - Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Completed NCT02978261 - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas Phase 1
Completed NCT01836536 - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients N/A
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Completed NCT01479686 - iMRI Guided Resection in Cerebral Glioma Surgery Phase 3
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A